Chartreusin (1) produced by Streptomyces chartreusis was originally reported in 1953,2) and its chemical structure ( Fig. 1 ) was fully elucidated in 1964.3>4) Originally chartreusin was studied because of its antibacterial activity, but latter its significant antitumor effect against murine L1210 and P388 leukemias, as well as against B16melanoma,were revealed.5) However,this antitumor activity of chartreusin were observed only when both the tumor cells and the drug were injected ip (ip-ip system). Under these conditions, chartreusin precipitated in the peritoneal cavity resulting in prolonged contact between the drug and the tumor cells. Whenthe drug was administered iv (ip-iv system), it was rapidly eliminated through the bile. Therefore the drug concentration fell below the effective dose quickly, and antitumor activity was not observed by iv route. 5) Oral (ip-po system) as well as subcutaneous (ip-sc system) administration of chartreusin also failed to observe a positive antitumor response. 5) Because of these drawbacks, chartreusin was not selected for clinical trials. Its novel structure and high activities against some experimental tumors suggested synthetic modification of chartreusin.
Until recently, no chartreusin derivative with improved antitumor activity has been reported. The replacement of the disaccharide moiety of chartreusin with neutral monosaccharide, as the only attempt to synthesize new derivatives, failed to develop a better compound than the original one.6) Recently the related antibiotic elsamicin, having an amino group on the sugar moiety, was isolated by Bristol-Myers' group.7) It was more effective than chartreusin against some murine tumors in ip-ip system, and also showed antitumor activity in both ip-iv and sc-iv systems. 8) To explore the structure-activity relationship of chartreusin derivatives, we have modified the hydroxyl groups of chartreusin.
Chemistry
The acetals ofchartreusin at 3',4'-dihydroxyl groups (listed in Table 1 ) were synthesized by the reaction with the corresponding aldehydes (ketones) or the dimethyl acetals in the presence of an acid catalyst as shown in Scheme 1.
In that way, it is possible to obtain a pair of isomers. The reaction with benzaldehyde resulted in a mixture of exo and endo benzylidene derivatives and the ratio ranged from 1 : 1 to 1 : 2. On the contrary, the reaction with an aliphatic aldehyde or ketone yielded nearly a single isomer (endo isomer). From these results, webelieve that the endo form is morestable thermodynamically than the exo form.
The configuration of these isomers were determined by the measurements of these differential nuclear Overhauser effects (dif-NOE): In the derivative 12, the irradiation of the benzyl proton resulted in the observation of the dif-NOE not on the 2'-H but on the 4'-H. In the other derivative 13 (the isomer of 12), the dif-NOE was observed reversely. On the basis of these NOEexperiments, the configurations of 12 and 13 were assigned the endo form ( Fig. 2(A) ) and the exo form ( Fig. 2(B) ), respectively. Scheme1. Synthesis of 3^4'-O-substituted chartreusin. In all aliphatic acetal derivatives except compound 9, the irradiation of the acetal-proton led to be observed the dif-NOE not on the 2'-H but on the 4'-H such as 12. Therefore, the configuration of these aliphatic derivatives (2~7) was determined to be the endo form. In the derivative 9, the reaction of chartreusin with methyl ethyl ketone resulted in a pair of the acetal isomers, but the evaluation of these isomers was carried out without separation because of the difficulty of separation. Phenol esters of 3/,4'-0-exo-benzylidene-chartreusin (13) (listed in Tables 3 and 4) were prepared by the condensation of the corresponding carboxylic acids using dicyclohexylcarbodiimide (DCC) as shown inScheme2.
In the case of 20, its intermediate was obtained by the reaction of 13 with JV-benzyloxycarbonyl-iVmethyl-/?-alanine in the same manner as described above, and the resulting compoundwas reduced with hydrogen in the presence of 5% palladium-carbon to obtain 20.
Antitumor Activity and Discussion In order to investigate the antitumor activity of the 3',4'-0-substituents of chartreusin, the cytostatic activity of these derivatives has been determined in ip-ip system against B16 melanoma. Table 1 shows that the activity of the 3',4'-0-substituted derivatives was compared with that of chartreusin. In the alkylidene series (2~10), the bulky substituent in 7 or 10 extinguished the antitumor activities, and the activities of all derivatives except 8 were lower than that of chartreusin. In case of the cyclohexylidene derivative (ll), which acetal moiety is larger than that of inactive 10 (the moiety is less bulky than that of 10), its antitumor activity was the same level as that of 2, 3 or 9. On the other hand, the benzylidene derivatives (12 and 13) were more potent than other derivatives, but a remarkable differences of the antitumor activity regarding with their stereoisomers also has been observed.
The exo type of 3',4'-0-benzylidene-chartreusin (13) was the most potent. Two derivatives (8 and 13) were further evaluated in ip-iv system against P388 leukemia, in which system chartreusin is inactive. Table 2 shows that 8 and 13 were active in this system. Onthe basis of the plasma pharmacokinetic profile,9) it is thought that the elimination of the drug to the biliary duct might be decreased by the introduction of these substituents.
Compared the two derivatives, 13 was more effective than 8 in both ip-ip and ip-iv systems. Although 13 was the most effective among the 3',4'-0-substituted derivatives, its antitumor activity against B16 melanoma(see Table 4 ) in the ip-po system was not outstanding. a The mixture ofisomers (ca. 1 : 1). Chartreusin was dissolved in 0.9% saline containing 20%dimethyl formamide; the others were suspended in 0.9% saline containing 10% Tween 80, and administered iv on days 1, 4 and 7.
13 was not metabolized to chartreusin in plasma and tissues, therefore 13 would not be a prodrug of chartreusin. Further modification of compound13 has been attempted to obtain broader antitumor spectra and a possible candidate for clinical investigation.
Eleven 6-0-acyl derivatives of compound13 were evaluated for antitumor activity against P388 leukemia in the ip-iv system (Table 3) .
Both lipophilic and hydrophilic substituent at 6-position led to high activity against P388 leukemia. The acylation of the phenol in 13 did not destroy its activity, when the substituent was relatively small. These results indicated that this modification would be useful to obtain derivatives which would have suitable physiological properties for different route of administration.
The compoundslisted in Table 4 were further evaluated for antitumor activities against several murine tumors in ip-po system (lipophilic derivatives) or ip-iv system (hydrophilic derivatives).
Lipophilic derivatives (15, 16, 22 and 24) did not show any activity against B16 melanoma in ip-po system when the drug was administered on days 1, 5 and 9, although they were active against P388 in ip-iv system (Tables 3 and 4) . Interestingly, the newly synthesized 25 had higher activity against B16 melanoma than the original compound (13) in ip-po system, and had also high potency against P388 and B16  B16  B16  B16  B16  B16  B16  B16  L1210  P388  B16  P388  B16  B16  L1210  P388  B16  L1210  P388 127 (75) 139 (75) (20) 147 (60) 209 (20) > 500 (60) 180 (20) 214 (60) 25 and 26 were suspended in distilled water containing 0.5% (w/v) sodium carboxymethyl cellulose; 19 and 20 were dissolved in 0.9%saline containing about 2%Tween80; the others were suspended in distilled water containing 5% dimethylformamide and 10% Tween 80; and administered po (lipophilic derivatives) or iv (hydrophilic derivatives) on days 1, 5 and 9. a Administered on days 1, 5, 9, 13 and 17.
L1210 leukemia. These findings suggested that 25 would have better lipophilicity to be absorbed from gastro-intestinal tract, and also indicated that the bioavailability of the derivatives might be deeply effected by the 6-0-substituent.
On the other hand, the hydrophilic derivatives (19 and 20) were not so active against B16, but they showed very remarkable antitumor activity against P388 and L1210 leukemia cell lines. Especially, their excellent activity against LI210 leukemia was detected, and in case of the higher dose, the T/C value was over 500 and several cured mice were observed. Although their potencies were almost the same against B16 melanoma, 19 was superior to 20 not only in its activity against P388 and L1210 leukemia but also in its solubility for the iv injection.
Both 25 and 19 turned out to be a prodrug of 13, because the ester of 6-0-position was rapidly hydrolyzed in plasma within about 30 minutes and also because the in vitro activity was disappeared by the blocking of the phenol at 6-position. Consequently, both compounds would be metabolized to the same active compound (13) in vivo (and in vitro), and these acyl substituents would be influenced on the pharmacokinetic parameters. Comparing the lipophilic 25 with the hydrophilic 19, it seems that a lipophilic derivative of 13 becamemore active against B16melanomaand that a hydrophilic one becamemore active against P388 and L1210 leukemia cell lines than the original compound (13). The variation of the 6-0-substituent altered the distribution in mice, and it is very likely that this was due to the altered uptake of the derivative into the cells. However, it is unclear whether there is any correlation between the hydrophilicity of the derivatives and their activity against solid tumor (B16 melanoma) or leukemia cell lines (P388 and L1210). There are not enough data available yet to clarify this question. This will be a future subject to be studied.
In conclusion, we found that 13 is a promising new derivative of chartreusin. Twomodified 13 such as 25 (with possible oral activity) and 19 (as possible intravenous drug) were obtained by the acylation of the phenol. These two compounds are interesting for further studies. Experimental MP's were determined with a Yanagimoto micro melting point apparatus, type MP-S3, and were not corrected. NMRspectra were recorded on a Jeol JNM-PMX-60spectrometer and a Jeol JNM-GSX-400 spectrometer. Chemical shifts are given in S values with tetramethylsilane as an internal standard.
Column chromatography was carried out with Silica gel 60 (E. Merck Co.). Preparative TLC was conducted on 20 x 20cm glass plates coated in our laboratory with a 0.6-0.7-mm thickness of Silica gel GF254 (E. Merck Co.). chloroform (20-30ml). The mixture was stirred at room temperature for 4-20 hours, then poured into saturated sodium bicarbonate and extracted with chloroform. The extract was washed with saturated brine, dried and concentrated to obtain crude product, which was purified by silica gel column chromatography (eluted with CHC13-MeOH)to give the desired product in about 80% yield. /?-toluenesulfonic acid (ca. 0.05mmol) and Molecular Sieves 4A or 5A (ca. 5 g) (or CuSO4: ca. 1 g) were added to a solution of chartreusin (1.0 mmol) in absolute chloroform (20 -30 ml). The mixture was stirred at room temperature for 5 -24 hours, then filtered into saturated sodium bicarbonate and extracted with chloroform. The extract was washed with saturated brine, dried and concentrated to afford crude product, which was purified by silica gel column chromatography (eluted with CHC13 -MeOH) to give the desired product in 30-70% yield.
3',4'-0-Endo-«-butylidenechartreusin (4) Synthesis of the Endo and Exo Forms of 3',4'-0-Benzylidene-chartreusins (12 and 13) Benzaldehyde (30 ml), /?-toluenesulfonic acid (1.0 g) and Molecular Sieves 4A (50 g) were added to a solution ofchartreusin (10.0 g) in absolute chloroform (300 ml). The mixture was stirred at room temperature for 20 hours, then filtered through Celite and the filtrate was concentrated to a volume of about 150ml. The resulting solution was subjected to several repetitions of silica gel column chromatography to obtain crystals of the endo (12) form and the exo (13) form of 3',4'-0-benzylidenechartreusin.
Both isomers were recrystallized from a mixture of chloroform and ethanol, and 4.8 g of the endo form and 2.7g of crystals of the exo form were obtained.
3',4'-6>-Endo-benzylidenechartreusin (12) 
Measurements of the Differential NOEs(Determination of Structural Isomers)
Differential NOEsspectra were recorded on a Jeol JNM-GSX-400 spectrometer using a pre-settled pulse-sequence mode (NOEDIF): Compound12 was dissolved in CDC13so that a 0.03-M solution was obtained. The benzyl proton of the benzylidene group was observed at 5.93 ppm as a singlet peak. Irradiation at this signal led to a 6.0% enhancement of the 4'-proton (S 4.15, dd, /=5.8 and 2.4Hz) absorption. The measurements of the dif-NOEs on 13 and 2~7 were done by the same way as that of 12. These irradiation peaks (acetal-proton) and the enhancements observed were follows: 13, Synthesis of 6-OAcyl-3',4'-0-exo-benzylidene-chartreusin (14~18 and 22~26)
General Procedure for 14~18 and 22~26: An appropriate carboxylic acid (0.15~0.3mmol) and dicyclohexylcarbodiimide (0.2~0.3 mmol) were added to a solution of 3',4'-Oexo-benzylidenechartreusin (13: 0. 1 mmol) in absolute chloroform (1.0 ml) and pyridine (1.0 ml), and the resulting mixture was stirred at room temperature for 3~20 hours. After completion of the reaction, a small amount of methanol (ca. 0.05~0.1 ml) and ethyl acetate (3~5 ml) were added, and the mixture was stirred for about 0.5 hour (urea was precipitated). The resulting suspension was filtered through Celite, and the filtrate was concentrated under reduced pressure to obtain crude product, which was directly purified by preparative TLC (CHC13 -MeOH, 30 : 1, multiple development) to give the desired product in 80-95% yield. .60 mmol) in absolute chloroform (40 ml) and pyridine (20 ml), and the resulting mixture was stirred at room temperature for 3.5 hours. After completion of the reaction, methanol (ca. 0.5 ml) and ethyl acetate (ca. 40ml) were added, and the mixture was stirred for 0.5 hour. The resulting suspension was filtered through Celite, and the filtrate was concentrated under reduced pressure to obtain crude crystals, which were recrystallized from a mixture of chloroform and ethyl acetate to give 6-O-(7V,A^-dimethylglycyl)-3',4'-O-exo-benzylidenechartreusin (2.7 g, 13 and urea was contained). The obtained crystals were further purified by the following partition extract method: The crystals were dissolved in chloroform (300 ml), then the solution was washed with water (100ml, twice), dil hydrochloric acid (ca. 0.005n: 100ml), water (100ml) and brine (100ml), then dried and concentrated at 5-20°C to obtain crude crystals (pyridine free), which were dissolved in 0. 1 n hydrochloric acid (40 ml) and water (260 ml). The resulting solution was filtered through a glass filter to give a clear solution (urea free), which was washed with ethyl acetate (100 ml, three times). After the addition of saturated sodium bicarbonate and brine, the washed solution (13 free) was extracted with chloroform. The extract was washed with water and brine, dried and concentrated to afford crystals, which were recrystallized from chloroform -ethyl acetate to give pure 6-O-(A^,iV-dimethylglycyl)-3' ,4' -O-exo-benzylidenechartreusin (2.26 g, 2.78 mmol) in
